respiratory pathogen panel (rpp) · 2019-09-24 · respiratory pathogen panel (rpp) available today...
TRANSCRIPT
• Influenza A• Influenza A H1• Influenza A H3• Influenza B• Respiratory Syncytial Virus A
(RSV A)• Respiratory Syncytial Virus B
(RSV B)• Parainfluenza 1• Parainfluenza 2• Parainfluenza 3
• Parainfluenza 4• Human Bocavirus• Human Metapneumovirus
(hMPV)• Rhinovirus/Enterovirus• Adenovirus• Coronavirus HKU1• Coronavirus NL63• Coronavirus OC43• Coronavirus 229E
Bacterial Targets
• Bordetella Pertussis• Bordetella Parapertussis• Chlamydophila Pneumonae• Mycoplasma Pneumoniae
Viral Targets
For more information, visit www.CoreBioLabs.com
3 FDA Cleared Testing3 Rapid Turnaround Time - 24 Hours After Receipt at lab3 Remarkable Detection Capabilities3 Comprehensive Panel of 22 Targets3 Closed-Tube System Minimizes Contamination Risks3 Minimal Hands-On Time3 Customizable, Scalable Throughput
Respiratory Pathogen Panel (RPP)Available today through CoreBioLabsAccurate, Reliable Data in a Fraction of the TimeCoreBioLabs uses the most advanced pathogen panel utilizing the latest FDA cleared platforms. It is a comprehensive, robust assay that detects multiple respiratory pathogens simultaneously in an easy-to-use system.
Flu seasons are unpredictable and vary in severity – statistics underscore the seriousness of the disease. It has been estimated that each year in the United States flu results in:1,2
Disease SummaryRespiratory Burden in the U.S.
• 31.4 million outpatient visits• About 200,000 hospitalizations
• More than $87 billion in total economicburden
Viruses Cases / Year Rate of Hospitalization Death Rate
Seasonal Flu25 – 50 million (U.S.)
600 million (world)
150,000 – 200,000 (U.S.)
3/1,000 (6 – 23 months)
9/1,000 (< 6 months)
36,000 (U.S)
250,000 – 500,000 (world)
RSV125,000 (U.S.)
64 million (world)
15 – 40% RTI (developing world)
70,000 – 126,000 (U.S. infants)
14,000 – 60,000 (U.S. elderly)
160,000 (world)
Para 118% URI
22% LRI
64% croup (U.S. children)
5,800 – 29,000 (U.S.) NA
Para 2 1,800 – 15,600 (U.S.) NA
Para 3 8,700 – 52,000 (U.S) NA
Bacterias 24.1 million NA 160,700 (world)
1. Molinari N-AM, et al. The annual impact of seasonal influenza in the USL Measureing disease burden and costs. Vaccine 2007;25:5086-50962. Morbidity and Mortality Weekly Report (MMWR): Estimates of Deaths Associated with seasonal Influeza - United States, 1976-2007. CDC (Internet) Cited October 2016.
August 27, 2010 / 59/(33);1057-10623. Acute Respiratory Infections. Who (Internet). Cited October 2016. Available from: http://www.who.int/vaccine_research/diseases/ari/en/index.html. 4. Olszewska and Openshaw Expert. Opin Emerg Drugs. 2009;14(2):207-217.5. National Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases (2017) Available from: https://www.cdc.gov/pertussis/fast-facts.html.
Reasons to be tested:• Deaths associated with respiratory
infections were 48,614 in 2003-04
• Respiratory symptoms can includecoughing, nasal discharge, congestion,fever, wheezing, headache, and myalgia
• Due to the similarity of diseases caused bymany viruses and bacteria, diagnosis basedon clinical symptoms alone is difficult
• In children, dual viral infections are common,with 1/3 of children having simultaneous viraland bacterial infections
• Pertussis can cause serious illness in people ofall ages and can even be life-threatening,especially in babies.5